Over the past few years, Germany has become a poster child for experimenting with pharma pricing and reimbursement. AMNOG has succeeded in lowering the government’s pharmaceutical bill, while reimbursement prices for new drugs have fallen below the EU average. Pharma companies seeking to enter the German market with new innovative therapies may benefit from important insights revealed here. (Source: PharmaTimes Digital, 6/5/15)
You are here: / / What Can We Learn From Germany’s AMNOG?